抗感染新药重组人溶菌酶的临床前评价  

Recombinant human lysozyme: a new antimicrobial drug

作　　者：吕秋军[1] 卞广兴[1] 

机构地区：[1]军事医学科学院放射与辐射医学研究所,北京100850

出　　处：《中国新药杂志》2006年第17期1436-1439,共4页Chinese Journal of New Drugs

摘　　要：重组人溶菌酶是经生物技术改构后产生的一类对G+和G-菌都有抗菌效应的一类新药。临床前数据表明它对1 040株致病菌具有抗菌活性,最低抑菌浓度(MIC)范围为0．125～>4000μg·mL-1;此外,它还有抑制冠状病毒、抗炎和镇痛作用。现综述其药效学、毒理学和药动学的研究情况。新型重组人溶菌酶在体内外均安全和有效,有望开发成为新型抗感染药物。A new human lysozyme made by recombinant techniques shows effectiveness in killing selectively Gram-negative bacteria as well as Gram-positive bacteria. Preclinical data indicated that the recombinant human lysozyme （rhLZ） significantly inhibited 1 040 strains of bacteria growth with a MIC of 0. 125 - 〉 4 000μg·mL^-1. The rhLZ shows significant susceptibilities against coronaviruses and inflammatory infection together with analgesic activity. This review discussed the toxicology, pharmacodynamics and pharmacokinetics of rhLZ. The rhLZ has the potential to be an effective and safe antimicrobials against the causative agent

关 键 词：重组人溶菌酶 药效学 毒理 药动学 

分 类 号：R969.1[医药卫生—药理学] R978.1[医药卫生—药学]